Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease affecting patients with obesity.
Why Is Novo Nordisk Stock Trading Higher On Friday?
Where Today's News Shapes Tomorrow
May 23, 2025
Headlines
